Compass Pathways set to join Canaccord Genuity's 45th Annual Growth Conference in Boston, Massachusetts on August 12, 2025.
Compass Pathways Plc, a London-based biotechnology company focused on revolutionising mental health treatment, has been granted the Innovative Licensing and Access Pathway (ILAP) designation in the UK for their treatment-resistant depression (TRD) drug, COMP360.
On August 12, 2025, Compass Pathways Plc will participate in the Canaccord Genuity 45th Annual Growth Conference in Boston, MA. The company presentation is scheduled for 4:00 pm ET and will provide insights into their groundbreaking work.
The presentation will be accessible via a live webcast from the 'Events' page in the Investors section of the Compass Pathways website. A replay of this webcast will be available for 30 days following the event. More information about Compass Pathways Plc can be found on their investor website.
COMP360, the company's proprietary formulation of synthesised psilocybin, has already received Breakthrough Therapy designation from the US Food and Drug Administration (FDA). This designation is given to drugs that have shown preliminary evidence of substantial improvement over existing treatments for serious or life-threatening conditions.
Compass Pathways Plc is dedicated to improving the lives of those living with mental health challenges who are not helped by existing standards of care. The company is pioneering the development of a new model of psilocybin treatment, with the vision of a world where mental health means the ability to thrive.
For investor enquiries, please contact Stephen Schultz at [email protected] or +1 401 290 7324. For media enquiries, please contact Dana Sultan-Rothman at [email protected] or +1 484 432 0041. Compass Pathways Plc also has offices in New York, US.
The source version of this news can be viewed on businesswire.com. We invite you to learn more about Compass Pathways Plc and their innovative approach to mental health treatment.
On August 12, 2025, during their presentation at the Canaccord Genuity 45th Annual Growth Conference in Boston, MA, Compass Pathways Plc will discuss their advancements in the field of technology-driven biotechnology and finance, specifically their groundbreaking work on treatment-resistant depression (TRD) drug, COMP360. A replay of this business event will be available for 30 days following the event on the 'Events' page in the Investors section of the Compass Pathways website.
